The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 11, 2018

Filed:

Jul. 30, 2014
Applicants:

Urgo Recherche Innovation ET Developpement, Chenove, FR;

Centre National DE LA Recherche Scientifique—cnrs, Paris, FR;

Universite Paris Diderot—paris 7, Paris, FR;

Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;

Ecole Normale Superieure, Paris, FR;

Inventors:

Claire Dugast-Darzacq, Antony, FR;

Maïté Noizet, Versailles, FR;

Xavier Darzacq, Antony, FR;

Beatrice Spiluttini Hebert, Houilles, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 48/00 (2006.01); A61K 31/713 (2006.01); A61K 31/715 (2006.01); C07H 21/04 (2006.01); A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61K 31/197 (2006.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01); A61L 15/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 9/0014 (2013.01); A61K 31/197 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); A61L 15/16 (2013.01); C12N 15/113 (2013.01); A61L 2300/432 (2013.01); C12N 2310/14 (2013.01);
Abstract

The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologs thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREB5, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologs thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.


Find Patent Forward Citations

Loading…